The Risk-Associated Long Noncoding RNA NBAT-1 Controls Neuroblastoma Progression by Regulating Cell Proliferation and Neuronal Differentiation

Abstract

Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblastoma associated transcript-1 (NBAT-1) as a biomarker significantly predicting clinical outcome of neuroblastoma. CpG methylation and a high-risk neuroblastoma associated SNP on chromosome 6p22 functionally contribute to NBAT-1 differential expression. Loss of NBAT-1 increases cellular proliferation and invasion. It controls these processes via epigenetic silencing of target genes. NBAT-1 loss affects neuronal differentiation through activation of the neuronal-specific transcription factor NRSF/REST. Thus, loss of NBAT-1 contributes to aggressive neuroblastoma by increasing proliferation and impairing differentiation of neuronal precursors.

Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion

“…An increasing amount of evidence has demonstrated that lncRNAs exhibit crucial regulatory roles in the biological processes of cancer, including genomic imprinting, chromatin modification and post-transcriptional processing (7)(8)(9)(10). Increasingly, studies have indicated that lncRNAs may be used as potential prognostic biomarkers and therapeutic targets (11,12).…”

Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells

“…Previous studies on novel lncRNAs have suggested that lncRNAs are characterized and important in the pathogenesis of cancer, rather than transcriptional noise (42)(43)(44). Accumulating evidence has shown that lncRNAs can drive carcinogenesis by promoting cell proliferation through the regulation of cell cycle and apoptosis (17,19,45). Studies have found that lncRNAs can be used in predicting survival rates in patients with glioma (46), and are potential biomarkers and therapeutic targets for glioma (47,48).…”

Risk stratification and therapeutics of neuroblastoma: the challenges remain

“…In addition, recent evidence shows the crucial roles of long non-coding RNA (lncRNA) in the tumorigenesis and progression of neuroblastoma, such as non-coding RNA expressed in aggressive neuro-blastoma, [22] neuroblastoma associated transcript-1, [23] paired box 6 upstream antisense RNA, [24] and MYCN opposite strand. [25] High levels of a novel lncRNA, named as lncUSMycN, are independently associated with poor clinical outcome of neuroblastoma patients.…”